TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02881606

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Naso-alveolar molding (NAM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer aided design NAM (CAD/NAM)
Study: NCT01586572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mOPV1
Description: Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mOPV1
Description: Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mOPV1
Description: Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bOPV 1,3
Description: The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
Study: NCT01129596

Intervention type: DRUG
Intervention: donepezil hydrochloride
Description: This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
Study: NCT03614156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration)
Study: NCT01876017

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intravenous transfer of Autologous (BMMNCs)
Description: Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
Study: NCT04287517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capacitive-Resistive Therapy
Description: Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Capacitive-Resistive Therapy
Description: Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
Study: NCT01321099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Description: Labeled iron as FeSO4 or NaFeEDTA added to a test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytase
Description: Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Labeled iron as FeSO4 added to a test meal with or without vitamin C
Study: NCT04615832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee Full Face Mask
Description: Full face mask for PAP therapy applied in a home environment
Study: NCT03530124

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: Advisory Committee on Immunization Practices (ACIP) Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBV
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IPV
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hib
Description: ACIP Recommended vaccine
Study: NCT03292367

Intervention type: PROCEDURE
Intervention: ldTRA
Description: After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
Study: NCT01543048

Intervention type: OTHER
Intervention: Study Follow-Up
Description: Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
Study: NCT01145976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cy-ATG
Description: Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu-ATG
Description: Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
Study: NCT02745119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
Study: NCT03651414

Intervention type: OTHER
Intervention: Clinical data collection
Description: There will not be any experimental intervention. The study will be conducted according with normal clinical practice.

Intervention type: OTHER
Intervention: Clinical data collection
Description: There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
Study: NCT02979548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
Study: NCT00183313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse case management
Description: Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes standard mental health services.
Study: NCT02980393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
Study: NCT03863769

Intervention type: OTHER
Intervention: Lumbar Spinal Stenosis
Description: Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
Study: NCT01579136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor
Description: The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
Study: NCT03229980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold blood cardioplegia (large volume)
Description: Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold blood cardioplegia (small volume)
Description: Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
Study: NCT02425943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid Sculptra Aesthetic
Study: NCT03016052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
Study: NCT00904592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qi ming granula
Description: Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid
Study: NCT00357903

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Etanercept
Description: Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
Study: NCT01405144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Description: 5% 5-fluoruracil cream, twice a day, during 3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Description: The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
Study: NCT03714880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 MG
Description: Ingestion of study medication vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Ingestion of study medication vs placebo
Study: NCT04607018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMA-zeolite
Description: subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMA-zeolite
Description: subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass).
Study: NCT02062619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based behavioural word reading therapy
Description: Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer-based behavioural word reading therapy
Description: Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Real tDCS 20 minutes per session, three times per week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS, 20 minutes per session, 3 sessions per week
Study: NCT00559819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (orange juice), same volume as alcohol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
Study: NCT04207632

Intervention type: DRUG
Intervention: Botulinum toxin type A injection
Description: Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
Study: NCT02481128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without preoperative access to lymphoscintigraphy findings
Description: axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
Study: NCT03494998

Intervention type: DIAGNOSTIC_TEST
Intervention: PAT-POPS
Description: Emergency Department-specific screening tool
Study: NCT01811966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Study: NCT02354430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water-exercise
Description: 1. An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~2. One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~3. Unsupervised water-exercises (The six AquaMama exercises)~4. Motivating weekly emails during the 12 week training period.~5. Brush up sessions is held once every month for guidance in performing the exercises.
Study: NCT00396253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: 2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
Study: NCT03806764

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling from prospective study participants will be taken for immune functions measurements
Study: NCT00926718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil infusion
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil infusion
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
Study: NCT04616989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education
Description: Provide psycho-education to members of the community

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Distribution of COVID-19 leaflets to members of the community
Study: NCT00699114

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose as powder in gelatine capsules, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg as powder in gelatine capsules, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600 mg as powder in gelatine capsules, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: Ibuprofen 800 mg as powder in gelatine capsules, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 500 mg
Description: Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 1000 mg
Description: Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg
Description: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
Study: NCT03413488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Apply exercise and kinesio taping for intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Apply only exercise intervention
Study: NCT03830307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2-Bridge
Description: NSS-2-Bridge auricular therapy will be given in addition to standard of care
Study: NCT00169065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study: NCT01649206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Radiofrequency Thermal Ablation
Description: Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
Study: NCT04287582

Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.

Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.

Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
Study: NCT03752437

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ACT (Activated Clotting Time)
Description: Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ACT (Activated Clotting Time)
Description: Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 300 IU of heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 300 IU of heparin
Study: NCT03521440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor Massage
Description: Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.